Recent News Releases

Dear Hemophilia B Community, We are writing to share an important update on the availability of HEMGENIX® (etranacogene dezaparvovec-drlb). CSL is currently experiencing a temporary global...

CSL Seqirus will supply its differentiated influenza vaccine portfolio and, with long-term partner Sinergium Biotech, will localize vaccine filling and distribution. The partnership will...

New $1.5 billion investment builds on over $3 billion already spent on CSL's U.S. operations since 2018 Expansion will create at least 300 new jobs and enhance production of plasma-derived...

FOR GLOBAL MEDIA CSL Seqirus will provide adjuvanted cell-based vaccines to support Canada, if an influenza pandemic is declared by the World Health Organization (WHO) Influenza viruses of...

Melbourne, 16 February 2026 CSL Seqirus, part of leading Australian biotechnology company CSL, has today announced that neffy® adrenaline (epinephrine) nasal spray is now available and has been...